New hope for FSGS? obinutuzumab trial targets tough cases
NCT ID NCT04983888
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug obinutuzumab in 20 adults with a kidney disease called primary FSGS. The participants had not responded well to or could not take standard treatments like steroids. The goal was to see if obinutuzumab could reduce protein leakage in the urine, a sign of kidney damage. The drug was given as two IV infusions two weeks apart, with a repeat course at six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Obinutuzumab (a monoclonal antibody given by IV infusion)
- What this could lead to
- If it works, this could offer a new treatment option for people with FSGS who do not respond to or cannot take standard therapies, potentially reducing protein in the urine and protecting kidney function.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. Obinutuzumab can cause infusion reactions and increase infection risk, and it is not yet proven to be better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.